Solvo signs deal
Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Biotech sro to provide the Hungarian firm’s drug transporter assays to its customers in the biopharmaceutical industry. The move came as a reaction to new FDA guidelines outlining which drug transporters should be investigated as part of an IND. Solvo has developed significant expertise in the field of drug transporters since 1999. According to company CSO Dr. Katya Tsaioun, the most recent findings on the role of drug transporters in causing toxicity and drug-drug interactions means that all firms need to begin to evaluate drug-transporter activity at the preclinical level.